By Abionic
PSP is measured exclusively on the abioSCOPE. Sepsis is a time-sensitive emergency and according to the Sepsis Alliance, 80% of sepsis-related deaths could be prevented, but it remains notoriously difficult to diagnose due to the non-specific nature of its symptoms, which often resemble those of other common conditions. Timely detection and intervention are critical, as delayed antibiotic therapy in septic shock increases mortality by 8% per hour. Pancreatic Stone Protein (PSP) has emerged as a promising biomarker for sepsis diagnosis and outcome prediction. PSP, secreted by the pancreas, plays a crucial role in the neutrophil response during sepsis. PSP runs exclusively on the abioSCOPE®, an award-winning rapid diagnostics platform that leverages nanofluidics to deliver lab-quality results from a drop of blood in 7 minutes. Seamlessly integrated into routine clinical workflows, the test delivers fast, accurate, and user-friendly results in critical care settings. By measuring PSP levels, which are directly linked to a patient’s risk of sepsis, the test enables healthcare professionals to activate sepsis bundles earlier and improve outcomes. PSP level rises up to 3 days before clinical recognition enabling faster intervention and improved outcomes. Higher performances to current Standard of Care in predicting ICU mortality, enabling clinicians to better evaluate disease severity. PSP is exclusively measured on the abioSCOPE® platform, delivering lab-quality results within minutes from a drop of blood.
